|
nike dunk sb midten / Website (15.8.11 03:52) In recent years, Crohn's disease (CD) of the rising incidence, biological agents infliximab (IFX) is a tumor necrosis factor-α monoclonal antibody, can promote mucosal healing in patients with CD. Objective: IFX therapy CD's efficacy. methods: July 2008 - June 2009, Shanghai Zhongshan Hospital, 16 cases of hospitalized patients with CD according to CDAI score and assess the severity of CD patients were divided into conventional treatment group and the IFX group, were to pour Mesalazine + Nison and IFX treatment after 8 weeks of treatment were compared CDAI score, WBC, ESR, CRP and ALB levels were: 11 patients with mild active CD in patients receiving conventional treatment, five patients with moderate activity in patients receiving IFX treatment after treatment, all patients achieved clinical remission, 2 patients with anal fistula in patients with mild active after the switch to conventional therapy achieved clinical remission IFX treatment also two groups CDAI score, ESR and CRP levels than before treatment significantly improved (P <0.05); IFX group CDAI score lower rate than conventional treatment group, the difference was statistically significant (P = 0.019). Conclusion: IFX clinical remission of CD is superior to conventional treatment, and may contribute to conventional treatment ineffective in patients with anal fistula healing. |
Verantwortlich für die Inhalte und Daten dieses Weblogs ist der Autor.
Datenschutzerklärung / Dein kostenloses Weblog bei 20six.de / myblog.de!
/ Rechtsschutzversicherung